Lecanemab phase 3 trial results presented at Alzheimer’s conference
The results from the Phase III Clarity AD trial of lecanemab (BAN2401), the experimental Alzheimer’s drug developed by Eisai Co Ltd and Biogen, were […]
Lecanemab phase 3 trial results presented at Alzheimer’s conference Read More »